SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata (INOD) is trending amid intense community debate surrounding an eagerly anticipated strategic partnership announcement, which the CEO indicated would occur soon, potentially with a defense sector leader. While many bulls foresee this deal solidifying INOD's market leadership in AI data training and government contracts, a vocal skeptical faction expresses frustration over past unfulfilled predictions and general market conditions affecting small-cap AI stocks.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Midnight ($NIGHT) is commanding significant market attention, driven by its current price action and exceptionally high trading volumes. The crypto community is actively debating its privacy-centric utility, strategic position within the Cardano ecosystem, and the effects of recent token distributions. Sentiment ranges from strong bullish predictions to cautious discussions about its long-term sustainability.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

Aave is trending as the community highlights its superior product-market fit and aggressive expansion, including the Aave V4 testnet, a new consumer savings app challenging traditional finance, and a proposed $50 million annual token buyback. Community discussion frequently contrasts Aave's strong market share and innovative features with competitors, positioning it as a leading DeFi protocol poised for significant growth and mainstream adoption.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

GBTC is trending amidst a heated debate over Bitcoin's market cycle, with many anticipating a significant decline as 'crypto winter' allegedly begins, citing historical patterns and market manipulation. Conversely, others foresee a strong rebound and new highs, driven by conviction in Bitcoin's long-term fundamentals and its perceived correlation with gold. The community is actively discussing whether bearish predictions or optimistic 'buy the dip' sentiment will dominate its price action.

PulteGroup, Inc. engages in the homebuilding business. The firm is also involved in mortgage banking and title and insurance brokerage operations. It operates through the Homebuilding and Financial services business segments. The Homebuilding segment includes operations from Connecticut, Maryland, Massachusetts, New Jersey, New York, Pennsylvania, Virginia, Georgia, North Carolina, South Carolina, Tennessee, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota, Missouri, Ohio, Texas, Arizona, California, Nevada, New Mexico, and Washington. The Financial Services segment is composed of mortgage banking and title operations. The company was founded by William J. Pulte in 1950 and is headquartered in Atlanta, GA.

PulteGroup Inc

PulteGroup is trending following strong quarterly financial results and significant share repurchase authorizations, signaling management confidence in its operational model. The community remains divided, with some anticipating sustained demand from structural housing shortages and potential mortgage rate relief, while others express caution regarding persistent affordability challenges and sector-wide margin pressures due to incentives.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is currently trending amidst discussions surrounding its unique on-chain AI capabilities and Bitcoin L2 integration via Chain Fusion, highlighted by emerging projects like Caffeine AI. Despite recent price volatility and community debates over tokenomics and perceived market manipulation, long-term holders express strong conviction in ICP's foundational technology as an undervalued "Cloud Killer" essential for true Web3 decentralization, setting it apart from other platforms.

D.R. Horton, Inc. engages in the construction and sale of single-family housing. It operates through the following geographical segments: Northwest, Southwest, South Central, Southeast, East, and North. The Northwest segment relates to Colorado, Oregon, Utah, and Washington. The Southwest segment covers Arizona, California, Hawaii, Nevada, and New Mexico. The South Central segment is involved in Arkansas, Oklahoma, and Texas. The Southeast segment refers to Alabama, Florida, Louisiana, and Mississippi. The East segment operates Georgia, North Carolina, South Carolina, and Tennessee. The North segment focuses on Delaware, Illinois, Indiana, Iowa, Kentucky, Maryland, Minnesota, Nebraska, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia. The company was founded by Donald Ray Horton in 1978 and is headquartered in Arlington, TX.

D.R. Horton Inc.

D.R. Horton is trending after its recent fiscal Q1 earnings surpassed expectations for both profit and revenue, with the company reaffirming its full-year guidance. This positive report has fueled optimism, yet community discussions remain divided, weighing the homebuilder's strategic focus on affordable housing against persistent concerns about rising interest rates, housing affordability, and potential future oversupply in the broader sector.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

ARS Pharmaceuticals is currently trending as its Neffy nasal spray demonstrates accelerating market adoption, bolstered by robust revenue growth and a substantial non-dilutive funding injection for global expansion. The community is actively discussing a significant short squeeze potential driven by high short interest and limited share availability, coupled with ongoing competitive dynamics in the epinephrine market and explorations into new indications like hives treatment.

Clearwater Analytics Holdings, Inc. engages in the provision of web-based investment portfolio accounting, reporting, and reconciliation services. It operates through the United States and Rest of World geographical segments. Its products include automated data aggregation and validation, investment accounting, integrated reporting tools, a user-friendly solution, and business-specific tools. The company was founded in 2004 and is headquartered in Boise, ID.

Clearwater Analytics Holdings Inc - Ordinary Shares Class A

Clearwater Analytics (CWAN) is a major topic of conversation due to active takeover speculation, with multiple private equity firms reportedly in advanced discussions to acquire the company. The community is intensely debating potential buyout valuations, with many hoping for a significant premium given the company's strong fundamentals and positioning as an institutional AI powerhouse. This heightened M&A interest, further fueled by activist investor Starboard Value taking a notable stake, is driving widespread discussion around a potential sales process.

Meritage Homes Corp. engages in the design and construction of single-family attached and detached homes. It operates through the Homebuilding and Financial Services segments. The Homebuilding segment acquires and develops lands, constructs homes, markets and sells those homes, and provides warranty and customer services. The Financial Services segment offers title and escrows, mortgage, and insurance services. The company was founded by Steven J. Hilton and William W. Cleverly in 1985 and is headquartered in Scottsdale, AZ.

Meritage Homes Corp.

Meritage Homes is trending after reporting strong recent earnings, showcasing robust demand for its affordable, move-in ready homes and an impressive increase in orders. The community is buzzing with optimism for the homebuilding sector, anticipating potential rate reductions to further fuel growth, while recognizing MTH's strategy to capture market share amid favorable demographics and limited existing home supply.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 14.6% during the 3rd quarter, according to its most recent filing with the...

Q4 Earnings Estimate for BCRX Issued By HC Wainwright

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a report issued on...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen ratings firms that are currently covering the...

<ul class="summary-bullets"><li>BioCryst said the approval follows positive interim data from a trial that showed the drug is safe and well-tolerated.</li><li>The company is also seeking approval for the drug’s use in the targeted age group in Europe, Japan, Canada, and other countries.&nbsp;</li><li>Orladeyo in capsule form is already FDA-approved for treating the disorder in those over 12 years of age.&nbsp;</li></ul>BioCryst Pharmaceuticals, Inc. (BCRX) has received approval from the U.S. Food and Drug Administration (FDA) for Orladeyo, an oral pellet formulation for the treatment of a rare genetic disorder in children.The approval comes after positive interim data from the APeX-P trial, which showed it is safe and well-tolerated and effectively reduces monthly HAE attacks in young children, the company said in a statement.BioCryst has also filed an application for the drug’s use with the European Medicines Agency and the Japan Pharmaceutical and Medical Devices Agency. The company said it is exploring additional regulatory filings in other global territories, including Canada.Shares of <a href="https://stocktwits.com/symbol/BCRX">BCRX</a> jumped over 4% on Friday morning at the time of writing.<h2 class="st-heading-2">Breakthrough Treatment For Young Children</h2>Hereditary angioedema (HAE) is a rare genetic disorder that can cause sudden and severe swelling in the skin, face, limbs, gut, and air pathways with potential life-threatening consequences.Orladeyo will become the first approved oral drug for the treatment of hereditary angioedema (HAE) in children aged 2 to 12, the company said. All other treatments for HAE in the market for the targeted demographic are currently administered intravenously or through injections.A capsule formulation of Orladeyo for treating HAE in children over 12 years and older adults received FDA approval in December 2020.“As we mark five years since ORLADEYO first transformed care for those with HAE ages 12 and older, this approval extends the benefits of oral prophylactic therapy to a vulnerable and important part of the HAE community, children ages 2 to less than 12. We couldn’t be more excited to bring this treatment option to these kids and their caregivers,” said Jon Stonehouse, chief executive officer of BioCryst.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, BCRX was among the top five trending stocks on Friday morning. The retail sentiment around BCRX jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained ‘high’ at the time of writing.<figure class="image"><img style="aspect-ratio:1267/136;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_12_at_6_36_49_PM_png_130ee4212d.webp" alt="BCRX sentiment and message volume on Stocktwits. " width="1267" height="136"></figure>One Stocktwits user commended the FDA news.<stembedurl>https://stocktwits.com/Kiwiarse/message/638975638</stembedurl>Shares of BCRX are down over 3% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today?

The FDA has approved the use of Orladeyo, an oral drug, for children aged 2–12 with a rare genetic disorder.

Equity

Hood River Capital Management LLC Buys New Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Hood River Capital Management LLC purchased a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the...

BioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 326.1% during the 2nd quarter, according to its most recent filing with...

JPMorgan Chase & Co. Grows Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

JPMorgan Chase & Co. boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 48.7% during the 2nd quarter, according to its most recent 13F filing with the...

BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2,103.7% in the 2nd quarter, according to the company in its most recent...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Alane Barnes Sells 19,770 Shares

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 19,770 shares of the business's stock in a transaction on Wednesday, December 3rd. The stock was sold at an...

Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 50,906 Shares of Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 50,906 shares of the company's stock in a transaction dated Tuesday, December 2nd. The stock was sold at an...

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCRX News

BCRXBiocryst Pharmaceuticals Inc.